0000899243-21-014861.txt : 20210405 0000899243-21-014861.hdr.sgml : 20210405 20210405171216 ACCESSION NUMBER: 0000899243-21-014861 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210401 FILED AS OF DATE: 20210405 DATE AS OF CHANGE: 20210405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lyon Joseph Douglas CENTRAL INDEX KEY: 0001817838 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 21806485 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-01 0 0001088856 CORCEPT THERAPEUTICS INC CORT 0001817838 Lyon Joseph Douglas C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 0 1 0 0 Chief Accounting Officer Common Stock 2021-04-01 4 M 0 25000 11.35 A 25000 D Common Stock 2021-04-01 4 S 0 25000 23.8812 D 0 D Stock Option (Right to Buy) 11.35 2021-04-01 4 M 0 25000 0.00 D 2029-02-08 Common Stock 25000 75000 D These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $23.79 to $24.13 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 8, 2019, so that the total number of shares subject to this option becomes fully vested and exercisable on February 8, 2023. /s/ Joseph Douglas Lyon 2021-04-05